Literature DB >> 7533436

Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome.

V P Scantlebury1, R Shapiro, J McCauley, M Jordan, C Vivas, W Irish, A Tzakis, D Ellis, N Gilboa, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7533436      PMCID： PMC2981411     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.

Authors:  J McCauley; R Shapiro; O Bronster; M Jordan; D Ellis; N Gilboa; V Scantlebury; C Jensen; A Jain; T Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Renal transplantation in 20 children with hemolytic-uremic syndrome.

Authors:  F J Eijgenraam; R A Donckerwolcke; L A Monnens; W Proesmans; E D Wolff; B van Damme
Journal:  Clin Nephrol       Date:  1990-02       Impact factor: 0.975

3.  Prognostic factors of hemolytic uremic syndrome in renal allografts.

Authors:  D Candinas; G Keusch; R Schlumpf; H R Burger; W Weder; F Largiadèr
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Post-transplantation outcome of patients with hemolytic-uremic syndrome: update.

Authors:  D Hébert; E M Kim; R K Sibley; M S Mauer
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714
  4 in total
  4 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 3.  The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.

Authors:  Chantal Loirat; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

Review 4.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Authors:  Kioa L Wijnsma; Caroline Duineveld; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2018-11-06       Impact factor: 3.714
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.